Company Name: |
Shanghai Chaolan Chemical Technology Center
|
Tel: |
021-QQ:65489617 15618227136 |
Email: |
Sales@ATKchemical.com |
Products Intro: |
Product Name:VU534 CAS:923509-20-0 Purity:98% Package:5MG;10MG;50MG;100MG,1G,5G,100G
|
Company Name: |
Bide Pharmatech Ltd.
|
Tel: |
400-1647117 13681763483 |
Email: |
product02@bidepharm.com |
Products Intro: |
Product Name:N-(5,7-Dimethylbenzo[d]thiazol-2-yl)-1-((4-fluorophenyl)sulfonyl)piperidine-4-carboxamide CAS:923509-20-0 Purity:98% Package:10mg;25mg;50mg;100mg;250mg; Remarks:BD02220991
|
Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
Tel: |
021-65675885 18964387627 |
Email: |
customer_service@efebio.com |
Products Intro: |
Product Name:VU534 CAS:923509-20-0 Purity:99% Package:1mg;5mg;10mg
|
N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecarboxamide manufacturers
- VU534
-
- $36.00 / 1mg
-
2024-11-19
- CAS:923509-20-0
- Min. Order:
- Purity: 99.22%
- Supply Ability: 10g
|
| N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecarboxamide Basic information |
| N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecarboxamide Chemical Properties |
density | 1.412±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | storage temp. | 2-8°C | solubility | DMSO: 2mg/mL, clear (Warmed) | form | Solid | pka | 10.26±0.70(Predicted) | color | White to off-white |
| N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecarboxamide Usage And Synthesis |
Biological Activity | Allosteric site-targeting, reversible, potent and selective N-Acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) activator.
VU534 is a non-cytotoxic (up to 30 μM in murine RAW264.7 and human HepG2 cultures), reversible, potent and selective N-Acyl-phosphatidylethanolamine-hydrolyzing phospholipase D activator (mouse EC50/Emax = 0.30 μM/2.1-fold, human EC50/Emax = 0.93 μM/1.8-fold, using respective recombinant NAPE-PLD) th at targets an allosteric site distinct from th at of PE, DCA, or LEI-401, showing only weak sEH inhibition (IC50/Emax = 1.2 μM/55%) and little potency toward FAAH. VU534 enhances murine BMDMs efferocytosis (by 1.65-fold with 6h 10 μM pretreatment) by activating cellular NAPE-PLD activity (EC50/Emax = 6.6 μM/1.6-fold in RAW264.7 and 1.5 μM/1.6-fold in HepG2). |
| N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecarboxamide Preparation Products And Raw materials |
|